Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024

September 30, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will co-host with the Icahn School of Medicine at Mount Sinai a scientific symposium entitled “ Next Generation...

Innate Pharma announces FDA clearance of the IND for IPH4502, a Nectin-4 ADC to be developed in solid tumors

September 23, 2024

IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “...

Innate Pharma reports First Half 2024 Business Update and Financial Results

September 12, 2024

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH6101 1 first-in-human study advanced to Phase 2 and initiation of...

Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024

September 9, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (...

Innate Pharma announces conference call and webcast for first half 2024 financial results and business update

September 5, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a...

Innate Pharma announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming investor...

Innate Pharma announces its participation in upcoming investor conference

August 1, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conference, detailed...

Number of shares and voting rights of Innate Pharma as of July 10, 2024

July 25, 2024

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...

Next Generation Immunotherapy Discoveries

Next Generation Immunotherapy Discoveries | October 3, 2024 | New-York and virtual

Read more about Next Generation Immunotherapy Discoveries